GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (OTCPK:SYGGF) » Definitions » Loans Receivable

SYGGF (Synairgen) Loans Receivable : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Synairgen Loans Receivable?

Synairgen's Loans Receivable for the quarter that ended in Jun. 2024 was $0.00 Mil.


Synairgen Loans Receivable Historical Data

The historical data trend for Synairgen's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synairgen Loans Receivable Chart

Synairgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synairgen Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Synairgen Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Synairgen Loans Receivable Related Terms

Thank you for viewing the detailed overview of Synairgen's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Synairgen Business Description

Traded in Other Exchanges
Address
Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.